eslicarbazepine acetate
Nervous system (N03)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
pharma · T Cell Lymphoma · Diabetes Mellitus · CRSP
S.A
S.A.
S.A drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Lorenzo, EU HQ
2011 Founded
50 Employees
Public company Type
CRSP · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Lorenzo, EU
- Founded
- 2011
- Employees
- 50
- Programs
- 14
- Drugs
- 8
- Patents
- 65
S.A pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
S.A drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
human fibrinogen
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in S.A's portfolio. Molecular target: Fibrinogen.
- Target
- Fibrinogen
- Mechanism
- Fibrinogen exogenous protein
-
ketoconazole
Antiinfectives for systemic use (J02)US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
lebrikizumab
Dermatologicals (D11)Dermatologicals (D11) compound in S.A's portfolio. Molecular target: Interleukin-13.
- Target
- Interleukin-13
- Mechanism
- Interleukin-13 inhibitor
-
mifamurtide
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in S.A's portfolio. Molecular target: Nucleotide-binding oligomerization domain-containing protein 2.
- Target
- Nucleotide-binding oligomerization domain-containing protein 2
- Mechanism
- Nucleotide-binding oligomerization domain-containing protein 2 other
-
mitotane
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cholesterol side-chain cleavage enzyme, mitochondrial.
- Target
- Cholesterol side-chain cleavage enzyme, mitochondrial
- Mechanism
- Cytochrome P450 11B1 inhibitor
-
Development asset linked to S.A in public FDA and regional records.
-
tirbanibulin
Dermatologicals (D06)US regulatory status: approved. Molecular target: Proto-oncogene tyrosine-protein kinase Src.
- Target
- Proto-oncogene tyrosine-protein kinase Src
- Mechanism
- Tyrosine-protein kinase SRC inhibitor